Lawrence Banks

List of Publications by Year
in descending order

140 papers	9,649 citations	46918 47 h-index	39575 94 g-index
141 all docs	141 docs citations	141 times ranked	7120 citing authors

#	Article	IF	Citations
1	Loss of the E6AP Ubiquitin Ligase Induces p53-Dependent Phosphorylation of Human Papillomavirus 18 E6 in Cells Derived from Cervical Cancer. Journal of Virology, 2022, 96, JVI0150321.	1.5	5
2	Clinical validation of full HR-HPV genotyping HPV Selfy assay according to the international guidelines for HPV test requirements for cervical cancer screening on clinician-collected and self-collected samples. Journal of Translational Medicine, 2022, 20, 231.	1.8	8
3	Human Papillomavirus 16 L2 Recruits both Retromer and Retriever Complexes during Retrograde Trafficking of the Viral Genome to the Cell Nucleus. Journal of Virology, 2021, 95, .	1.5	12
4	Words of Advice: How to be a good Principal Investigator. FEBS Journal, 2021, 288, 3973-3977.	2.2	0
5	Human Papillomavirus Infection Requires the CCT Chaperonin Complex. Journal of Virology, 2021, 95, .	1.5	11
6	Welcome to Tumour Virus Research. Tumour Virus Research, 2021, 11, 200211.	1.5	0
7	Human papillomavirus E6 and E7: What remains?. Tumour Virus Research, 2021, 11, 200213.	1.5	53
8	The Dimeric Form of HPV16 E6 Is Crucial to Drive YAP/TAZ Upregulation through the Targeting of hScrib. Cancers, 2021, 13, 4083.	1.7	7
9	Human DLG1 and SCRIB Are Distinctly Regulated Independently of HPV-16 during the Progression of Oropharyngeal Squamous Cell Carcinomas: A Preliminary Analysis. Cancers, 2021, 13, 4461.	1.7	4
10	The Not-So-Good, the Bad and the Ugly: HPV E5, E6 and E7 Oncoproteins in the Orchestration of Carcinogenesis. Viruses, 2021, 13, 1892.	1.5	44
11	Spotlight on COVIDâ€19: eighteen months on. FEBS Journal, 2021, 288, 4992-4995.	2.2	2
12	Inhibition of kinase IKKÎ² suppresses cellular abnormalities induced by the human papillomavirus oncoprotein HPV 18E6. Scientific Reports, 2021, 11, 1111.	1.6	2
13	The biology of papillomavirus PDZ associations: what do they offer papillomaviruses?. Current Opinion in Virology, 2021, 51, 119-126.	2.6	8
14	A novel small-molecule inhibitor of the human papillomavirus E6-p53 interaction that reactivates p53 function and blocks cancer cells growth. Cancer Letters, 2020, 470, 115-125.	3.2	39
15	Human papillomavirus oncoproteins and post-translational modifications: generating multifunctional hubs for overriding cellular homeostasis. Biological Chemistry, 2020, 401, 585-599.	1.2	12
16	Spotlight on COVIDâ€19: from biology to therapy and prevention. FEBS Journal, 2020, 287, 3606-3608.	2.2	6
17	Human Papillomavirus 58 E7 T20I/G63S Variant Isolated from an East Asian Population Possesses High Oncogenicity. Journal of Virology, 2020, 94, .	1.5	8
18	HPV Oncoproteins and the Ubiquitin Proteasome System: A Signature of Malignancy?. Pathogens, 2020, 9, 133.	1.2	36

#	Article	IF	Citations
19	Acquisition of a phospho-acceptor site enhances HPV E6 PDZ-binding motif functional promiscuity. Journal of General Virology, 2020, 101, 954-962.	1.3	8
20	SGEF forms a complex with Scribble and Dlg1 and regulates epithelial junctions and contractility. Journal of Cell Biology, 2019, 218, 2699-2725.	2.3	21
21	Choosing the right path: membrane trafficking and infectious entry of small DNA tumor viruses. Current Opinion in Cell Biology, 2019, 59, 112-120.	2.6	5
22	Highlights in Virology: Viral miRNAs and Flaviviruses. Frontiers in Cellular and Infection Microbiology, 2019, 9, 54.	1.8	0
23	The HPV-18 E7 CKII phospho acceptor site is required for maintaining the transformed phenotype of cervical tumour-derived cells. PLoS Pathogens, 2019, 15, e1007769.	2.1	32
24	Diverse Papillomavirus Types Induce Endosomal Tubulation. Frontiers in Cellular and Infection Microbiology, 2019, 9, 175.	1.8	4
25	Phosphorylation of Human Papillomavirus Type 16 L2 Contributes to Efficient Virus Infectious Entry. Journal of Virology, 2019, 93, .	1.5	11
26	PDZ Domain-Containing Protein NHERF-2 Is a Novel Target of Human Papillomavirus 16 (HPV-16) and HPV-18. Journal of Virology, 2019, 94, .	1.5	14
27	Oncogenic comparison of human papillomavirus type 58 E7 variants. Journal of Cellular and Molecular Medicine, 2019, 23, 1517-1527.	1.6	9
28	Oncogenicitiy Comparison of Human Papillomavirus Type 52 E6 Variants. Journal of General Virology, 2019, 100, 484-496.	1.3	8
29	Identification of E6AP-independent degradation targets of HPV E6. Journal of General Virology, 2019, 100, 1674-1679.	1.3	10
30	HPV-16 virions can remain infectious for 2 weeks on senescent cells but require cell cycle re-activation to allow virus entry. Scientific Reports, 2018, 8, 811.	1.6	8
31	Human Papillomavirus 16 Infection Induces VAP-Dependent Endosomal Tubulation. Journal of Virology, 2018, 92, .	1.5	15
32	Upsetting the Balance: When Viruses Manipulate Cell Polarity Control. Journal of Molecular Biology, 2018, 430, 3481-3503.	2.0	25
33	Papillomaviruses and Endocytic Trafficking. International Journal of Molecular Sciences, 2018, 19, 2619.	1.8	27
34	Mechano-Dependent Phosphorylation of the PDZ-Binding Motif of CD97/ADGRE5 Modulates Cellular Detachment. Cell Reports, 2018, 24, 1986-1995.	2.9	29
35	The Human Papillomavirus E6 PDZ Binding Motif Links DNA Damage Response Signaling to E6 Inhibition of p53 Transcriptional Activity. Journal of Virology, 2018, 92, .	1.5	26
36	The PTPN14 Tumor Suppressor Is a Degradation Target of Human Papillomavirus E7. Journal of Virology, 2017, 91, .	1.5	68

#	Article	IF	Citations
37	Monitoring HPV-16 E7 phosphorylation events. Virology, 2017, 503, 70-75.	1.1	14
38	The VPS4 component of the ESCRT machinery plays an essential role in HPV infectious entry and capsid disassembly. Scientific Reports, 2017, 7, 45159.	1.6	22
39	Viral oncoproteins and ubiquitination: accessing a cellular toolbox for modifying protein function. FEBS Journal, 2017, 284, 3168-3170.	2.2	1
40	Human Papillomavirus 16 (HPV-16), HPV-18, and HPV-31 E6 Override the Normal Phosphoregulation of E6AP Enzymatic Activity. Journal of Virology, 2017, 91, .	1.5	9
41	Retriever is a multiprotein complex for retromer-independent endosomal cargo recycling. Nature Cell Biology, 2017, 19, 1214-1225.	4.6	243
42	In Vivo Functional Selection Identifies Cardiotrophin-1 as a Cardiac Engraftment Factor for Mesenchymal Stromal Cells. Circulation, 2017, 136, 1509-1524.	1.6	28
43	A naturally occurring variant of HPV-16 E7 exerts increased transforming activity through acquisition of an additional phospho-acceptor site. Virology, 2017, 500, 218-225.	1.1	26
44	Molecular mechanisms underlying human papillomavirus E6 and E7 oncoprotein-induced cell transformation. Mutation Research - Reviews in Mutation Research, 2017, 772, 23-35.	2.4	123
45	Characterizing the spatio-temporal role of sorting nexin 17 in human papillomavirus trafficking. Journal of General Virology, 2017, 98, 715-725.	1.3	10
46	Mitotic control of human papillomavirus genome-containing cells is regulated by the function of the PDZ-binding motif of the E6 oncoprotein. Oncotarget, 2017, 8, 19491-19506.	0.8	14
47	Analysis of Multiple HPV E6 PDZ Interactions Defines Type-Specific PDZ Fingerprints That Predict Oncogenic Potential. PLoS Pathogens, 2016, 12, e1005766.	2.1	61
48	A Drosophila Model of HPV E6-Induced Malignancy Reveals Essential Roles for Magi and the Insulin Receptor. PLoS Pathogens, 2016, 12, e1005789.	2.1	12
49	The high-risk HPV E6 target scribble (hScrib) is required for HPV E6 expression in cervical tumour-derived cell lines. Papillomavirus Research (Amsterdam, Netherlands), 2016, 2, 70-77.	4.5	23
50	Increased Growth of a Newly Established Mouse Epithelial Cell Line Transformed with HPV-16 E7 in Diabetic Mice. PLoS ONE, 2016, 11, e0164490.	1.1	4
51	Interaction of the Human Papillomavirus E6 Oncoprotein with Sorting Nexin 27 Modulates Endocytic Cargo Transport Pathways. PLoS Pathogens, 2016, 12, e1005854.	2.1	39
52	The Human Papillomavirus E6 PDZ Binding Motif: From Life Cycle to Malignancy. Viruses, 2015, 7, 3530-3551.	1.5	100
53	PDZRN3/LNX3 Is a Novel Target of Human Papillomavirus Type 16 (HPV-16) and HPV-18 E6. Journal of Virology, 2015, 89, 1439-1444.	1.5	15
54	High risk HPV E6 oncoproteins impair the subcellular distribution of the four and a half LIM-only protein 2 (FHL2). Virology, 2015, 476, 100-105.	1.1	2

#	Article	IF	Citations
55	Characterization of Novel Transcripts of Human Papillomavirus Type 16 Using Cap Analysis Gene Expression Technology. Journal of Virology, 2015, 89, 2448-2452.	1.5	6
56	A Novel PDZ Domain Interaction Mediates the Binding between Human Papillomavirus 16 L2 and Sorting Nexin 27 and Modulates Virion Trafficking. Journal of Virology, 2015, 89, 10145-10155.	1.5	55
57	Human Papillomavirus Infectious Entry and Trafficking Is a Rapid Process. Journal of Virology, 2015, 89, 8727-8732.	1.5	22
58	HPV-16 impairs the subcellular distribution and levels of expression of protein phosphatase 1Î³ in cervical malignancy. BMC Cancer, 2015, 15, 230.	1.1	5
59	Cancer-Causing Human Papillomavirus E6 Proteins Display Major Differences in the Phospho-Regulation of Their PDZ Interactions. Journal of Virology, 2015, 89, 1579-1586.	1.5	38
60	A new approach for screening cervical cancer by characterization of transcripts using CAGE technology.. Journal of Clinical Oncology, 2015, 33, e16514-e16514.	0.8	1
61	Human papillomavirus (HPV)â€•18 E6 oncoprotein interferes with the epithelial cell polarity Par3 protein. Molecular Oncology, 2014, 8, 533-543.	2.1	39
62	Restoration of MAGI-1 Expression in Human Papillomavirus-Positive Tumor Cells Induces Cell Growth Arrest and Apoptosis. Journal of Virology, 2014, 88, 7155-7169.	1.5	45
63	The human papillomavirus (HPV) E6 oncoproteins promotes nuclear localization of active caspase 8. Virology, 2014, 450-451, 146-152.	1.1	35
64	Human papillomavirus infection requires the TSG101 component of the ESCRT machinery. Virology, 2014, 460-461, 83-90.	1.1	31
65	ZASP Interacts with the Mechanosensing Protein Ankrd2 and p53 in the Signalling Network of Striated Muscle. PLoS ONE, 2014, 9, e92259.	1.1	29
66	The role of inflammation in HPV infection of the Oesophagus. BMC Cancer, 2013, 13, 185.	1.1	24
67	Interactions between E6AP and E6 proteins from alpha and beta HPV types. Virology, 2013, 435, 357-362.	1.1	23
68	HPV E6 oncoprotein as a potential therapeutic target in HPV related cancers. Expert Opinion on Therapeutic Targets, 2013, 17, 1357-1368.	1.5	26
69	SNX17 Facilitates Infection with Diverse Papillomavirus Types. Journal of Virology, 2013, 87, 1270-1273.	1.5	44
70	Interaction of HPV E6 oncoproteins with specific proteasomal subunits. Virology, 2013, 446, 389-396.	1.1	11
71	High-Risk Human Papillomavirus E6 Oncoproteins Interact with 14-3-3Î¶ in a PDZ Binding Motif-Dependent Manner. Journal of Virology, 2013, 87, 1586-1595.	1.5	74
72	The Role of Protein Kinase A Regulation of the E6 PDZ-Binding Domain during the Differentiation-Dependent Life Cycle of Human Papillomavirus Type 18. Journal of Virology, 2013, 87, 9463-9472.	1.5	56

#	Article	IF	Citations
73	A Novel Interaction between hScrib and PP1Î³ Downregulates ERK Signaling and Suppresses Oncogene-Induced Cell Transformation. PLoS ONE, 2013, 8, e53752.	1.1	30
74	The Invasive Capacity of HPV Transformed Cells Requires the hDlg-Dependent Enhancement of SGEF/RhoG Activity. PLoS Pathogens, 2012, 8, e1002543.	2.1	33
75	Human tumour viruses and the deregulation of cell polarity in cancer. Nature Reviews Cancer, 2012, 12, 877-886.	12.8	60
76	Human papillomaviruses and the specificity of PDZ domain targeting. FEBS Journal, 2012, 279, 3530-3537.	2.2	84
77	The Biology and Life-Cycle of Human Papillomaviruses. Vaccine, 2012, 30, F55-F70.	1.7	1,042
78	Differential Regulation of Cell-Cell Contact, Invasion and Anoikis by hScrib and hDlg in Keratinocytes. PLoS ONE, 2012, 7, e40279.	1.1	21
79	Regulation of the DLG tumor suppressor by Î²â€catenin. International Journal of Cancer, 2012, 131, 2223-2233.	2.3	18
80	Human Papillomavirus L2 Facilitates Viral Escape from Late Endosomes via Sorting Nexin 17. Traffic, 2012, 13, 455-467.	1.3	111
81	Regulation of translational efficiency by different splice variants of the Disc large 1 oncosuppressor 5â€²â€UTR. FEBS Journal, 2011, 278, 2596-2608.	2.2	13
82	Stabilization of HPV16 E6 protein by PDZ proteins, and potential implications for genome maintenance. Virology, 2011, 414, 137-145.	1.1	49
83	Regulation of the Human Papillomavirus Type 18 E6/E6AP Ubiquitin Ligase Complex by the HECT Domain-Containing Protein EDD. Journal of Virology, 2011, 85, 3120-3127.	1.5	53
84	E6 and E7 from Human Papillomavirus Type 16 Cooperate To Target the PDZ Protein Na/H Exchange Regulatory Factor 1. Journal of Virology, 2011, 85, 8208-8216.	1.5	55
85	A Systematic Analysis of Human Papillomavirus (HPV) E6 PDZ Substrates Identifies MAGI-1 as a Major Target of HPV Type 16 (HPV-16) and HPV-18 Whose Loss Accompanies Disruption of Tight Junctions. Journal of Virology, 2011, 85, 1757-1764.	1.5	74
86	PDZ domains: the building blocks regulating tumorigenesis. Biochemical Journal, 2011, 439, 195-205.	1.7	90
87	Interaction of viral oncoproteins with cellular target molecules: infection with highâ€risk vs lowâ€risk human papillomaviruses. Apmis, 2010, 118, 471-493.	0.9	125
88	Modification of Human Papillomavirus Minor Capsid Protein L2 by Sumoylation. Journal of Virology, 2010, 84, 11585-11589.	1.5	33
89	The mechanisms and implications of hScrib regulation of ERK. Small GTPases, 2010, 1, 108-112.	0.7	11
90	The Human Papillomavirus (HPV) E6* Proteins from High-Risk, Mucosal HPVs Can Direct Degradation of Cellular Proteins in the Absence of Full-Length E6 Protein. Journal of Virology, 2009, 83, 9863-9874.	1.5	49

#	Article	IF	Citations
91	CDK phosphorylation of the discs large tumour suppressor controls its localisation and stability. Journal of Cell Science, 2009, 122, 65-74.	1.2	30
92	The high-risk HPV E6 oncoprotein preferentially targets phosphorylated nuclear forms of hDlg. Virology, 2009, 387, 1-4.	1.1	23
93	The stability of the human papillomavirus E6 oncoprotein is E6AP dependent. Virology, 2009, 393, 7-10.	1.1	66
94	Comparative transforming potential of different human papillomaviruses associated with non-melanoma skin cancer. Virology, 2008, 371, 374-379.	1.1	30
95	Analysis of specificity determinants in the interactions of different HPV E6 proteins with their PDZ domain-containing substrates. Virology, 2008, 376, 371-378.	1.1	40
96	The E6E7 oncoproteins of cutaneous human papillomavirus type 38 interfere with the interferon pathway. Virology, 2008, 377, 408-418.	1.1	48
97	Regulation of the hDlg/hScrib/Hugl-1 tumour suppressor complex. Experimental Cell Research, 2008, 314, 3306-3317.	1.2	26
98	Cloning and functional analysis of the promoter region of the human Disc large gene. Gene, 2008, 424, 87-95.	1.0	11
99	Structures of a Human Papillomavirus (HPV) E6 Polypeptide Bound to MAGUK Proteins: Mechanisms of Targeting Tumor Suppressors by a High-Risk HPV Oncoprotein. Journal of Virology, 2007, 81, 3618-3626.	1.5	107
100	Human discs large and scrib are localized at the same regions in colon mucosa and changes in their expression patterns are correlated with loss of tissue architecture during malignant progression. International Journal of Cancer, 2006, 119, 1285-1290.	2.3	132
101	The hScrib/Dlg apico-basal control complex is differentially targeted by HPV-16 and HPV-18 E6 proteins. Oncogene, 2005, 24, 6222-6230.	2.6	118
102	Activation of the protein kinase B pathway by the HPV-16 E7 oncoprotein occurs through a mechanism involving interaction with PP2A. Oncogene, 2005, 24, 7830-7838.	2.6	157
103	In Vitro Assays of Substrate Degradation Induced by High-Risk HPV E6 Oncoproteins. , 2005, 119, 411-418.		5
104	Degradation of hDlg and MAGIs by human papillomavirus E6 is E6-AP-independent. Journal of General Virology, 2004, 85, 2815-2819.	1.3	51
105	HPV E6 specifically targets different cellular pools of its PDZ domain-containing tumour suppressor substrates for proteasome-mediated degradation. Oncogene, 2004, 23, 8033-8039.	2.6	112
106	HPV-18 E6*I modulates HPV-18 full-length E6 functions in a cell cycle dependent manner. International Journal of Cancer, 2004, 110, 928-933.	2.3	29
107	Differential expression of the human homologue ofdrosophila discs large oncosuppressor in histologic samples from human papillomavirus-associated lesions as a marker for progression to malignancy. International Journal of Cancer, 2004, 111, 373-380.	2.3	78
108	Inhibition of E6-induced Degradation of its Cellular Substrates by Novel Blocking Peptides. Journal of Molecular Biology, 2004, 335, 971-985.	2.0	46

#	Article	IF	Citations
109	Ubiquitination and proteasome degradation of the E6 proteins of human papillomavirus types 11 and 18. Journal of General Virology, 2004, 85, 1419-1426.	1.3	27
110	Viruses and the 26S proteasome: hacking into destruction. Trends in Biochemical Sciences, 2003, 28, 452-459.	3.7	106
111	Activity of the human papillomavirus E6 PDZ-binding motif correlates with an enhanced morphological transformation of immortalized human keratinocytes. Journal of Cell Science, 2003, 116, 4925-4934.	1.2	110
112	Regulation of the Discs Large Tumor Suppressor by a Phosphorylation-dependent Interaction with the Î²-TrCP Ubiquitin Ligase Receptor. Journal of Biological Chemistry, 2003, 278, 42477-42486.	1.6	41
113	Changes in expression of the human homologue of the Drosophila discs large tumour suppressor protein in high-grade premalignant cervical neoplasias. Carcinogenesis, 2002, 23, 1791-1796.	1.3	70
114	Complementation of a p300/CBP defective-binding mutant of adenovirus E1a by human papillomavirus E6 proteins. Journal of General Virology, 2002, 83, 829-833.	1.3	14
115	Oncogenic human papillomavirus E6 proteins target the MAGI-2 and MAGI-3 proteins for degradation. Oncogene, 2002, 21, 5088-5096.	2.6	188
116	Chimaeric HPV E6 proteins allow dissection of the proteolytic pathways regulating different E6 cellular target proteins. Oncogene, 2002, 21, 8140-8148.	2.6	33
117	Comparative Analysis of the Intracellular Location of the High- and Low-Risk Human Papillomavirus Oncoproteins. Virology, 2002, 293, 20-25.	1.1	49
118	Mutational analysis of the discs large tumour suppressor identifies domains responsible for human papillomavirus type 18 E6-mediated degradation. Journal of General Virology, 2002, 83, 283-289.	1.3	33
119	Regulation of the human papillomavirus oncoproteins by differential phosphorylation. Molecular and Cellular Biochemistry, 2001, 227, 137-144.	1.4	10
120	HPV E6 and MAGUK protein interactions: determination of the molecular basis for specific protein recognition and degradation. Oncogene, 2001, 20, 5431-5439.	2.6	109
121	The Human Papillomavirus E6 protein and its contribution to malignant progression. Oncogene, 2001, 20, 7874-7887.	2.6	446
122	The HPV-16 E7 oncoprotein binds Skip and suppresses its transcriptional activity. Oncogene, 2001, 20, 7677-7685.	2.6	41
123	Proteasome-mediated regulation of the hDlg tumour suppressor protein. Journal of Cell Science, 2001, 114, 4285-4292.	1.2	45
124	HPV E6 targeted degradation of the discs large protein: evidence for the involvement of a novel ubiquitin ligase. Oncogene, 2000, 19, 719-725.	2.6	94
125	Interactions of the PDZ-protein MAGI-1 with adenovirus E4-ORF1 and high-risk papillomavirus E6 oncoproteins. Oncogene, 2000, 19, 5270-5280.	2.6	281
126	Differential regulation of human papillomavirus E6 by protein kinase A: conditional degradation of human discs large protein by oncogenic E6. Oncogene, 2000, 19, 5884-5891.	2.6	64

#	Article	IF	Citations
127	Differential Phosphorylation of the HPV-16 E7 Oncoprotein during the Cell Cycle. Virology, 2000, 276, 388-394.	1.1	45
128	Role of Bak in UV-induced apoptosis in skin cancer and abrogation by HPV E6 proteins. Genes and Development, 2000, 14, 3065-3073.	2.7	284
129	Multi-PDZ Domain Protein MUPP1 Is a Cellular Target for both Adenovirus E4-ORF1 and High-Risk Papillomavirus Type 18 E6 Oncoproteins. Journal of Virology, 2000, 74, 9680-9693.	1.5	258
130	Inhibition of E6 induced degradation of p53 is not sufficient for stabilization of p53 protein in cervical tumour derived cell lines. Oncogene, 1999, 18, 3309-3315.	2.6	48
131	Oncogenic human papillomavirus E6 proteins target the discs large tumour suppressor for proteasome-mediated degradation. Oncogene, 1999, 18, 5487-5496.	2.6	285
132	The role of the E6-p53 interaction in the molecular pathogenesis of HPV. Oncogene, 1999, 18, 7690-7700.	2.6	379
133	HPV-18 E6*I protein modulates the E6-directed degradation of p53 by binding to full-length HPV-18 E6. Oncogene, 1999, 18, 7403-7408.	2.6	83
134	Interaction between the HPV-16 E2 transcriptional activator and p53. Oncogene, 1999, 18, 7748-7754.	2.6	79
135	Role of a p53 polymorphism in the development of human papilloma-virus-associated cancer. Nature, 1998, 393, 229-234.	13.7	897
136	p53 polymorphism and risk of cervical cancer. Nature, 1998, 396, 532-532.	13.7	9
137	Inhibition of Bak-induced apoptosis by HPV-18 E6. Oncogene, 1998, 17, 2943-2954.	2.6	265
138	Alternatively spliced HPV-18 E6* protein inhibits E6 mediated degradation of p53 and suppresses transformed cell growth. Oncogene, 1997, 15, 257-264.	2.6	115
139	Repression of p53 Transcriptional Activity by the HPV E7 Proteins. Virology, 1997, 227, 255-259.	1.1	62
140	The Human Papillomavirus Type 16 E5 Gene Cooperates with the E7 Gene to Stimulate Proliferation of Primary Cells and Increases Viral Gene Expression. Virology, 1994, 203, 73-80.	1.1	131